Form 4: Upstream Bio Director Daniella Beckman Acquires Stock Options

Sentiment:

SEC Form 4 Filing


Director Daniella Beckman acquired stock options for 34,681 shares of Upstream Bio, Inc. on October 10, 2024.

Summary

  • Daniella Beckman, a director of Upstream Bio, Inc., filed a Form 4 on October 15, 2024, reporting a transaction.
  • On October 10, 2024, Beckman acquired stock options for 34,681 shares of Upstream Bio's common stock at an exercise price of $17.
  • The options vest in 36 equal monthly installments starting October 10, 2024, contingent upon Beckman's continued service.
  • The options expire on October 9, 2034.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing related to stock option grants.

Positives

  • The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

  • The transaction could have a minor positive impact on shareholder sentiment, reflecting insider confidence.

Key Dates

DateDescription
10/10/2024Date of stock option acquisition
10/10/2024Vesting start date
10/09/2034Stock option expiration date
10/15/2024Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.